First-line treatment of advanced ALK-positive non-small-cell lung cancer

Shipra Gandhi,1 Hongbin Chen,2 Yujie Zhao,2 Grace K Dy2 1Department of Internal Medicine, State University of New York, 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gandhi S, Chen H, Zhao Y, Dy GK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/67a00b2a4f4c4ec59b7bd979698c07ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67a00b2a4f4c4ec59b7bd979698c07ea
record_format	dspace
spelling	oai:doaj.org-article:67a00b2a4f4c4ec59b7bd979698c07ea2021-12-02T07:06:45ZFirst-line treatment of advanced ALK-positive non-small-cell lung cancer1179-2728https://doaj.org/article/67a00b2a4f4c4ec59b7bd979698c07ea2015-09-01T00:00:00Zhttps://www.dovepress.com/first-line-treatment-of-advanced-alk-positive-non-small-cell-lung-canc-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Shipra Gandhi,1 Hongbin Chen,2 Yujie Zhao,2 Grace K Dy2 1Department of Internal Medicine, State University of New York, 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within the US and worldwide. There have been major treatment advances in NSCLC over the past decade with the discovery of molecular drivers of NSCLC, which has ushered in an era of personalized medicine. There are several actionable genetic aberrations in NSCLC, such as epidermal growth factor receptor and anaplastic lymphoma kinase (ALK). In 3%–7% of NSCLC, a chromosomal inversion event in chromosome 2 leads to fusion of a portion of the ALK gene with the echinoderm microtubule–associated protein-like 4 (EML4) gene. The constitutive activation of the ALK fusion oncogene renders it vulnerable to therapeutic intervention. This review focuses on the first-line treatment of advanced ALK-positive NSCLC using ALK inhibitors. Crizotinib was the first agent proven to be efficacious as first-line treatment for ALK-positive NSCLC. However, acquired resistance inevitably develops. The central nervous system is a sanctuary site that represents a common site for disease progression as well. Hence, more potent, selective next-generation ALK inhibitors that are able to cross the blood–brain barrier have been developed for treatment against crizotinib-resistant ALK-positive NSCLC and are also currently being evaluated for first-line therapy as well. In this review, we provide summary of the clinical experience with these drugs in the treatment of ALK-positive NSCLC. Keywords: non-small-cell lung cancer, ALK, first line, crizotinib, pemetrexedGandhi SChen HZhao YDy GKDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 71-82 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Gandhi S Chen H Zhao Y Dy GK First-line treatment of advanced ALK-positive non-small-cell lung cancer
description	Shipra Gandhi,1 Hongbin Chen,2 Yujie Zhao,2 Grace K Dy2 1Department of Internal Medicine, State University of New York, 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within the US and worldwide. There have been major treatment advances in NSCLC over the past decade with the discovery of molecular drivers of NSCLC, which has ushered in an era of personalized medicine. There are several actionable genetic aberrations in NSCLC, such as epidermal growth factor receptor and anaplastic lymphoma kinase (ALK). In 3%–7% of NSCLC, a chromosomal inversion event in chromosome 2 leads to fusion of a portion of the ALK gene with the echinoderm microtubule–associated protein-like 4 (EML4) gene. The constitutive activation of the ALK fusion oncogene renders it vulnerable to therapeutic intervention. This review focuses on the first-line treatment of advanced ALK-positive NSCLC using ALK inhibitors. Crizotinib was the first agent proven to be efficacious as first-line treatment for ALK-positive NSCLC. However, acquired resistance inevitably develops. The central nervous system is a sanctuary site that represents a common site for disease progression as well. Hence, more potent, selective next-generation ALK inhibitors that are able to cross the blood–brain barrier have been developed for treatment against crizotinib-resistant ALK-positive NSCLC and are also currently being evaluated for first-line therapy as well. In this review, we provide summary of the clinical experience with these drugs in the treatment of ALK-positive NSCLC. Keywords: non-small-cell lung cancer, ALK, first line, crizotinib, pemetrexed
format	article
author	Gandhi S Chen H Zhao Y Dy GK
author_facet	Gandhi S Chen H Zhao Y Dy GK
author_sort	Gandhi S
title	First-line treatment of advanced ALK-positive non-small-cell lung cancer
title_short	First-line treatment of advanced ALK-positive non-small-cell lung cancer
title_full	First-line treatment of advanced ALK-positive non-small-cell lung cancer
title_fullStr	First-line treatment of advanced ALK-positive non-small-cell lung cancer
title_full_unstemmed	First-line treatment of advanced ALK-positive non-small-cell lung cancer
title_sort	first-line treatment of advanced alk-positive non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/67a00b2a4f4c4ec59b7bd979698c07ea
work_keys_str_mv	AT gandhis firstlinetreatmentofadvancedalkpositivenonsmallcelllungcancer AT chenh firstlinetreatmentofadvancedalkpositivenonsmallcelllungcancer AT zhaoy firstlinetreatmentofadvancedalkpositivenonsmallcelllungcancer AT dygk firstlinetreatmentofadvancedalkpositivenonsmallcelllungcancer
_version_	1718399575018962944

First-line treatment of advanced ALK-positive non-small-cell lung cancer

Ejemplares similares